CymaBay Therapeutics Overview
- Year Founded
-
1988
- Status
-
Acquired/Merged
- Employees
-
101
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$4.3B
CymaBay Therapeutics General Information
Description
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Contact Information
Website
www.cymabay.comCorporate Office
- 7601 Dumbarton Circle
- Fremont, CA 94555
- United States
Corporate Office
- 7601 Dumbarton Circle
- Fremont, CA 94555
- United States
CymaBay Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 21. Merger/Acquisition | 22-Mar-2024 | $4.3B | Completed | Generating Revenue/Not Profitable | ||
| 20. 2PO | 12-Sep-2023 | Completed | Generating Revenue/Not Profitable | |||
| 19. 2PO | 24-Jan-2023 | Completed | Generating Revenue/Not Profitable | |||
| 18. 2PO | 19-Jul-2017 | Completed | Generating Revenue/Not Profitable | |||
| 17. PIPE | 19-Jul-2017 | Completed | Generating Revenue/Not Profitable | |||
| 16. 2PO | 15-Jul-2015 | Completed | Generating Revenue/Not Profitable | |||
| 15. IPO | 27-Jan-2014 | Completed | Profitable | |||
| 14. Debt - General | 11-Dec-2013 | Completed | Profitable | |||
| 13. Later Stage VC | 31-Oct-2013 | $30.2M | $249M | Completed | Profitable | |
| 12. Later Stage VC | 10-Nov-2009 | $5.58M | $219M | Completed | Generating Revenue |
CymaBay Therapeutics Comparisons
Industry
Financing
Details
CymaBay Therapeutics Competitors (99)
One of CymaBay Therapeutics’s 99 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Denovo Biopharma | Venture Capital-Backed | Hangzhou, China |
CymaBay Therapeutics Patents
CymaBay Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240252500-A1 | Treatment of chronic pruritic dermatoses | Pending | 29-Jan-2023 | ||
| US-20240252499-A1 | Treatment of uremic pruritus | Pending | 29-Jan-2023 | ||
| US-20220241228-A1 | Treatment of cholangiopathies | Pending | 01-Feb-2021 | ||
| AU-2022214948-B2 | Treatment of cholangiopathies with seladelpar | Active | 01-Feb-2021 | ||
| CA-3203235-A1 | Treatment of cholangiopathies with seladelpar | Active | 01-Feb-2021 | A61K31/192 |
CymaBay Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CymaBay Therapeutics Former Investors (29)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abbott Ventures | Corporate Venture Capital | Minority | ||
| AllianceBernstein | Asset Manager | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority |
CymaBay Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 11, 2023
36.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
CymaBay Therapeutics FAQs
-
When was CymaBay Therapeutics founded?
CymaBay Therapeutics was founded in 1988.
-
Where is CymaBay Therapeutics headquartered?
CymaBay Therapeutics is headquartered in Fremont, CA.
-
What is the size of CymaBay Therapeutics?
CymaBay Therapeutics has 101 total employees.
-
What industry is CymaBay Therapeutics in?
CymaBay Therapeutics’s primary industry is Biotechnology.
-
Is CymaBay Therapeutics a private or public company?
CymaBay Therapeutics is a Private company.
-
What is the current valuation of CymaBay Therapeutics?
The current valuation of CymaBay Therapeutics is .
-
What is CymaBay Therapeutics’s current revenue?
The current revenue for CymaBay Therapeutics is .
-
How much funding has CymaBay Therapeutics raised over time?
CymaBay Therapeutics has raised $655M.
-
Who are CymaBay Therapeutics’s investors?
Abbott Ventures, AllianceBernstein, Alta Partners, Avoro Capital, and Bay City Capital are 5 of 29 investors who have invested in CymaBay Therapeutics.
-
Who are CymaBay Therapeutics’s competitors?
NGM Biopharmaceuticals, Abeona Therapeutics, Regulus Therapeutics, Adaptimmune Therapeutics, and Denovo Biopharma are some of the 99 competitors of CymaBay Therapeutics.
-
When was CymaBay Therapeutics acquired?
CymaBay Therapeutics was acquired on 22-Mar-2024.
-
Who acquired CymaBay Therapeutics?
CymaBay Therapeutics was acquired by Gilead Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
